Clinical Utility for Respiratory and Allergy Medicine
ME/CFS research has generated diagnostic and therapeutic insights with broader applicability to respiratory and allergy medicine, suggesting that pneumologists and allergologists are well-positioned to contribute to both ME/CFS research and management of related conditions in general practice.
1 Transferable Diagnostic Techniques
1.1 Two-Day Cardiopulmonary Exercise Testing
The two-day CPET protocol, which objectively quantifies post-exertional malaise through measurement of performance decline between testing days in positive studies (Lim et al. 2020) (contested by null replication (Mancini et al. 2026)), has utility beyond ME/CFS diagnosis:
- Distinguishing deconditioning from pathology: In disability evaluations, malingering concerns, or contested diagnoses, day-2 performance decline provides objective biomarker
- Post-viral assessment: Identifying which respiratory infection survivors require specialized chronic illness management vs. standard recovery
- Exercise prescription safety: Determining whether exercise rehabilitation is appropriate or contraindicated The meta-analysis by Lim et al. demonstrated significant workload decline at ventilatory threshold in ME/CFS patients (-14.6W) while controls showed improvement (+6.5W, p=0.01), providing reproducible objective measurement.
1.2 Capnography in Orthostatic Assessment
Standard vital sign monitoring misses orthostatic hypocapnia, present in 20.6% of ME/CFS patients vs. 2.9% of controls (Natelson et al. 2022). Integration of capnography during tilt-table testing or simple lean tests can identify:
- Breathing pattern disorders causing “unexplained” dizziness or brain fog
- Hypocapnic cerebral hypoperfusion (25% drop in CO2, 50% drop in brain blood flow)
- Patients whose orthostatic symptoms will respond to breathing retraining rather than pharmacologic intervention
1.3 Gas Exchange Analysis During Exercise
ME/CFS research has clarified that severe dyspnea can occur despite normal pulmonary function tests, with the primary pathology involving peripheral oxygen extraction at the skeletal muscle level rather than central cardiopulmonary dysfunction (Joseph et al. 2023). This insight prevents unnecessary invasive testing and redirects clinical investigation toward appropriate mechanisms.
2 Underdiagnosed Comorbidities in Allergy Practice
2.1 Mast Cell Activation Syndrome
MCAS develops in approximately 25% of ME/CFS patients over the disease course (Wirth and Scheibenbogen 2023), but prevalence in general allergy practice populations remains understudied. The condition is likely underdiagnosed due to:
- Non-specific symptoms overlapping with common allergic conditions
- Lack of widely available, validated diagnostic criteria
- Episodic nature making timing of testing challenging Simple therapeutic trials with H1/H2 antihistamine combinations (e.g., loratadine + famotidine) show 72% response rates in Long COVID/ME/CFS populations, suggesting empiric trials may be both diagnostic and therapeutic for patients with treatment-resistant “allergic” symptoms.
2.2 Histamine Intolerance
While affecting only 1–3% of the general population, histamine intolerance appears markedly more prevalent in ME/CFS, Long COVID, and fibromyalgia. Recognition of this pattern may identify an underserved patient subgroup in allergy practices.
4 Research Opportunities
Areas where respiratory and allergy medicine expertise could advance ME/CFS understanding:
- Ventilation-perfusion mismatch mechanisms: Indirect evidence exists from elevated VE/VCO2 ratios; direct V/Q scanning studies are lacking
- Respiratory muscle function: Objective diaphragm function assessment in patients reporting respiratory muscle fatigue
- MCAS prevalence in general populations: Establishing baseline rates in allergy practice for comparison to ME/CFS cohorts
- Breathing pattern disorder interventions: Capnometry-guided retraining protocols adapted for ME/CFS energy limitations